In the published article, there was an error in the Funding statement. “This work was supported by Scientific research project of Hunan Provincial Health Commission (No. 202103030980) and Graduate Research Innovation Project of Central South University.” The correct Funding statement appears below.
Statements
Funding
This work was supported by Scientific research project of Hunan Provincial Health Commission (No. 202103030980) and the Fundamental Research Funds for the Central Universities of Central South University (No. 2022ZZTS0860)”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
histone deacetylase 6, histone deacetylase inhibitor, ACY-1215, cancer, neurological diseases, inflammatory diseases
Citation
Li J, Yu M, Fu S, Liu D and Tan Y (2022) Corrigendum: Role of selective histone deacetylase 6 inhibitor ACY-1215 in cancer and other human diseases. Front. Pharmacol. 13:1117936. doi: 10.3389/fphar.2022.1117936
Received
07 December 2022
Accepted
08 December 2022
Published
14 December 2022
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
13 - 2022
Updates
Copyright
© 2022 Li, Yu, Fu, Liu and Tan.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yuyong Tan, tanyuyong@csu.edu.cn; Deliang Liu, deliangliu@csu.edu.cn
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.